BioAgilytix

Activities: Research & Development Analysis

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  3. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  4. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  5. Bio-Rad and Oncocyte partner to commercialise transplant monitoring with Droplet Digital PCR The collaboration aims to provide researchers with tools to enable transformational monitoring of key biomarkers in solid tissue transplants

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Analysis

Evolving needs of biosimilar immunogenicity assays

The competitive nature of the ever-expanding biosimilars market is putting pressure on developers to achieve approval at accelerated speed. However, success in this endeavour will only come with robust bioanalytical methods that demonstrate biosimilar comparability with the innovator
Digital

BioAgilytix achieves cybersecurity accreditation

BioAgilytix Labs has secured a valuable seal of approval for the safety of its IT systems and processes
Research & Development

BioAgilytix appoints Euan Menzies as Chair and Chief Executive Officer

BioAgilytix, a leading global contract research organisation focused on supporting pharmaceutical and biotech partners in all phases of drug development, announces the appointment, effective immediately, of Euan Menzies as Chair and CEO
Research & Development

Overcoming bioanalytical hurdles in the pharma and life sciences sector

A new era of innovation and advancement in drug design, and modalities such as cell and gene therapies (CGTs), have led to the development of promising new treatments in a wide array of therapeutic areas; these include rare diseases, genetic disorders, various cancers and musculoskeletal conditions
Research & Development

BioAgilytix accelerates global expansion with the acquisition of IPM Biotech

Transaction expands BioAgilytix's global footprint and adds immunogenicity, pharmacokinetics and pharmacodynamics (PD) expertise to the portfolio
Research & Development

BioAgilytix acquires IPM Biotech

Expands and enhances the global reach and breadth of its bioanalytical capabilities
Subscribe now